These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 33833592)

  • 1. Review on Experimental Treatment Strategies Against
    Mazzeti AL; Capelari-Oliveira P; Bahia MT; Mosqueira VCF
    J Exp Pharmacol; 2021; 13():409-432. PubMed ID: 33833592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
    Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
    Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
    Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ergosterol biosynthesis and drug development for Chagas disease.
    Urbina JA
    Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination With Tomatidine Improves the Potency of Posaconazole Against
    Rocha-Hasler M; de Oliveira GM; da Gama AN; Fiuza LFA; Fesser AF; Cal M; Rocchetti R; Peres RB; Guan XL; Kaiser M; Soeiro MNC; Mäser P
    Front Cell Infect Microbiol; 2021; 11():617917. PubMed ID: 33747979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
    Palace-Berl F; Pasqualoto KFM; Zingales B; Moraes CB; Bury M; Franco CH; da Silva Neto AL; Murayama JS; Nunes SL; Silva MN; Tavares LC
    Eur J Med Chem; 2018 Jan; 144():29-40. PubMed ID: 29247858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease.
    Gomes DC; Medeiros TS; Alves Pereira EL; da Silva JFO; de Freitas Oliveira JW; Fernandes-Pedrosa MF; de Sousa da Silva M; da Silva-Júnior AA
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.
    Franco CH; Warhurst DC; Bhattacharyya T; Au HYA; Le H; Giardini MA; Pascoalino BS; Torrecilhas AC; Romera LMD; Madeira RP; Schenkman S; Freitas-Junior LH; Chatelain E; Miles MA; Moraes CB
    Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():107-120. PubMed ID: 32688218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutical approaches under investigation for treatment of Chagas disease.
    Bahia MT; Diniz Lde F; Mosqueira VC
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1225-37. PubMed ID: 24855989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment.
    Aguilera E; Varela J; Serna E; Torres S; Yaluff G; Bilbao NV; Cerecetto H; Alvarez G; González M
    Mem Inst Oswaldo Cruz; 2018 Mar; 113(3):153-160. PubMed ID: 29412353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chagas disease: progress and new perspectives.
    Sánchez-Sancho F; Campillo NE; Páez JA
    Curr Med Chem; 2010; 17(5):423-52. PubMed ID: 20015038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole.
    Téllez J; Romero I; Romanha AJ; Steindel M
    Parasit Vectors; 2019 May; 12(1):262. PubMed ID: 31126349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
    de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
    Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
    Palace-Berl F; Pasqualoto KF; Jorge SD; Zingales B; Zorzi RR; Silva MN; Ferreira AK; de Azevedo RA; Teixeira SF; Tavares LC
    Eur J Med Chem; 2015; 96():330-9. PubMed ID: 25899337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
    Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities.
    Porta EOJ; Kalesh K; Steel PG
    Front Pharmacol; 2023; 14():1233253. PubMed ID: 37576826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.